Ewing’s Sarcoma Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. Gradalis 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. Incyte Corporation 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Pfizer Inc. 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. Oncternal Therapeutics 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. Eisai Co., Ltd. 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. SillaJen Inc 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. MacroGenics, Inc. 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Celgene Corporation 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. NANTWORKS 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. Pfizer Inc. 6.10.1. Introduction 6.10.2. Financials 6.10.3. Products and Services 6.10.4. SWOT 6.11. Tyme Technologies, Inc. 6.11.1. Introduction 6.11.2. Financials 6.11.3. Products and Services 6.11.4. SWOT 6.12. TESARO, Inc 6.12.1. Introduction 6.12.2. Financials 6.12.3. Products and Services 6.12.4. SWOT 6.13. NanoValent Pharmaceuticals 6.13.1. Introduction 6.13.2. Financials 6.13.3. Products and Services 6.13.4. SWOT 6.14. PharmaMar 6.14.1. Introduction 6.14.2. Financials 6.14.3. Products and Services 6.14.4. SWOT 6.15. Salarius Pharmaceuticals LLC 6.15.1. Introduction 6.15.2. Financials 6.15.3. Products and Services 6.15.4. SWOT 6.16. NewVac LLC 6.16.1. Introduction 6.16.2. Financials 6.16.3. Products and Services 6.16.4. SWOT 6.17. CELLECTAR BIOSCIENCES, INC. 6.17.1. Introduction 6.17.2. Financials 6.17.3. Products and Services 6.17.4. SWOT 6.18. NanoSmart Pharmaceuticals, Inc. 6.18.1. Introduction 6.18.2. Financials 6.18.3. Products and Services 6.18.4. SWOT 6.19. Oncoceutics, Inc. 6.19.1. Introduction 6.19.2. Financials